Shanghai United Imaging Healthcare Co., Ltd. · Class II · Cleared Jul 16, 2025
| K-number | K243397 |
| Device name | uMR 680 |
| Applicant | Shanghai United Imaging Healthcare Co., Ltd. |
| Product code | LNH |
| Device class | Class II |
| Decision date | Jul 16, 2025 |
| Decision | Substantially Equivalent |
| Regulation | 892.1000 |
The uMR 680 is a 1.5T superconducting magnetic resonance diagnostic device with a 70cm patient bore that produces sagittal, transverse, coronal, and oblique cross-sectional and spectroscopic images to display internal anatomical structure and function of the head, body, and extremities. It is intended for use in diagnostic imaging where images and derived physical parameters, when interpreted by trained physicians, may assist in diagnosis.
The proposed device maintains identical fundamental specifications to the predicate device: 1.5T superconducting magnet, 70cm bore, 45mT/m max gradient amplitude, 200T/m/s max slew rate, and up to 96 receive channels. Key additions include new RF coils (Breast Coil-12, Head Coil-16), modified table dimensions, new pulse sequences (gre_snap, epi_dwi_msh, svs_hise, etc.), and new imaging processing features (AI-assisted Compressed Sensing, SparkCo artifact correction, Inline ECV/MOCO, 4D Flow, CEST, T1rho, and workflow enhancements).
IEC 60601-2-33 (MR equipment safety), IEC 60601-1-2 (EMC), NEMA MS 1-9 and MS 14 (SNR, geometric distortion, uniformity, SAR, slice thickness, RF coil heating), IEC 62304 (software lifecycle), ISO 10993 (biocompatibility), and ISO 14971 (risk management).
The device employs the same basic MR operating principles and fundamental magnet/RF/gradient system specifications as the predicate device with identical indications for use. All new features (coils, sequences, reconstruction algorithms, processing functions) are either incremental additions to existing capabilities or have predicate equivalents in reference devices. Clinical image quality was verified by board-certified radiologists, and machine learning algorithms (ACS, SparkCo, Inline ECV/MOCO) underwent performance validation showing safety and effectiveness profiles similar to existing cleared technologies, with no new safety or effectiveness concerns raised by the modifications.
View the full FDA submission: accessdata.fda.gov